On November 4, 2021 Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC) platform, reported upcoming presentations at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 36th Annual Meeting, taking place virtually and in person in Washington, DC, on November 10–14, 2021, and at the Connective Tissue Oncology Society’s (CTOS) Annual Meeting, being held virtually on November 10–13, 2021 (Press release, Shasqi, NOV 4, 2021, View Source [SID1234594531]). Shasqi will present updated data from its Phase 1 clinical study of SQ3370 in patients with advanced solid tumors, and nonclinical data on SQ3370 in combination with cancer immunotherapies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We look forward to these upcoming presentations where we will share the progress of our Phase 1 study, present data on the compatibility of SQ3370 treatment with a local immune response and increases in certain circulating immune cells, and review nonclinical evidence that our click-chemistry approach has additional potential when combined with other cancer therapies," said José M. Mejía Oneto, M.D., Ph.D., Founder and CEO of Shasqi.
SITC Meeting:
Title: Pharmacokinetic and immunologic data from a Phase I study of the click chemistry-based therapy SQ3370 in advanced solid tumors and soft-tissue sarcoma provides proof-of-concept for the CAPAC platform
Presentation number: 367
Date and time: Friday, Nov. 12, 2021, 7 AM – 8:30 PM EST
Presenter: Vivek A. Bhadri, M.D., Ph.D., Medical Oncologist at Chris O’Brien Lifehouse in Australia
Title: Combination of click chemistry-based SQ3370 with immunotherapies enhances antitumor effect in murine tumors with minimized systemic toxicity
Presentation number: 695
Date and time: Friday, Nov. 12, 2021, 7 AM – 8:30 PM EST
Presenter: Amir Mahmoodi, Scientist at Shasqi
CTOS Meeting:
Title: First-in-human trial of SQ3370 in relapsed or refractory soft tissue sarcoma and other solid tumors: proof-of-concept for the click chemistry-based CAPAC platform
Presentation number: P 182
Date and time: Friday, Nov. 12, 2021, 2:30 – 3:15 PM EST
Presenter: Alexander Guminski, M.D., Ph.D., Medical Oncologist at Royal North Shore Hospital in Australia
Title: Click Activated Protodrugs Against Cancer (CAPAC) Platform Enhances Antitumor Efficacy, Safety and Pharmacokinetics of Cancer Therapeutics
Presentation number: P 019
Date and time: Thursday, Nov. 11, 2021, 2:30 – 3:15 PM EST
Presenter: Sangeetha Srinivasan, Ph.D., Associate Director at Shasqi
CAPAC and SQ3370:
SQ3370 utilizes Shasqi’s proprietary CAPAC platform, a click chemistry-based approach that activates cancer drugs at the site of a tumor with decreased systemic toxicity. The investigational product is based on the chemical reaction between an attenuated trans-cyclooctene-modified protodrug and a tetrazine-modified biopolymer. The biopolymer is injected into the target tumor lesion, where it precisely activates an intravenously infused protodrug. Unlike traditional targeted therapies, the CAPAC platform is agnostic to tumor characteristics that can vary from patient to patient, such as biomarker expression and enzymatic activity.